Posted by Michael Wonder on 23 Apr 2020
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
21 April 2020 - Approval is based on the SENSCIS study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD.
Boehringer Ingelheim today announced that the European Commission has approved nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.
The approval comes after the Committee for Medicinal Products for Human Use had adopted a positive opinion for nintedanib in treatment of SSc-ILD on 27 February 2020.
